Standard BioTools Inc. LAB 深 滬
已收盤 02-06 16:00:00 美东时间
1.26
+0.020
+1.61%
華盛通- 最 高1.295
- 今 開1.28
- 成交量 109.93万股
- 最 低 1.25
- 昨 收 1.24
- 總市值 4.85亿
- 52周最高 1.72
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 0.92
- 委 比 81.24%
- 總股本 3.85亿
- 歷史最高 49.455
- 量 比 1.02
- 振 幅 3.63%
- 歷史最低 0.92
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Standard BioTools Completes Sale Of SomaLogic To Illumina For Up To $425M Plus Royalties
Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout paymentsApproximately $550 Million in cash & cash equivalents on balance sheet at close, excluding
01-30 22:14
Standard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools completed the sale of SomaLogic to Illumina for $350 million upfront, plus up to $75 million in earnouts and royalties. The transaction enhances the company's financial position, with $550 million in cash to fuel M&A growth. CEO Michael Egholm highlighted the strategic transformation and strengthened financial standing. The deal includes IP licenses and royalty streams, positioning the company for future expansion.
01-30 14:09
Neogen Posts Strong Q2 Earnings, Joins Astronics, Lockheed Martin, Constellation Brands And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on T...
01-08 23:20
Standard BioTools Reports $56M Q4 Preliminary Revenue And $185M In FY2025 Preliminary Revenue
Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools" or the "Company") today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter
01-08 20:18
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
Standard BioTools Inc. reported preliminary, unaudited 2025 revenue of approximately $185 million for the combined company and $85 million from continuing operations, exceeding expectations. CEO Michael Egholm highlighted steady execution, cost optimization, and a focus on profitability amid macro challenges. The company expects to close the sale of SomaLogic to Illumina in the first half of 2026, resulting in $550 million in cash and a stronger ...
01-08 12:00
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Shares of Heartbeam Inc (NASDAQ:BEAT) rose sharply in pre-market trading after ...
2025-11-28 17:49
Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Gorilla Technology Group Inc. (NASDAQ:GRRR) rose sharply in pre-marke...
2025-11-18 19:10
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
TD Cowen Maintains Hold on Standard BioTools, Lowers Price Target to $1.35
TD Cowen analyst Kyle Boucher maintains Standard BioTools (NASDAQ:LAB) with a Hold and lowers the price target from $1.55 to $1.35.
2025-11-06 02:35
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
Standard BioTools Inc. (NASDAQ: LAB) will release its third quarter 2025 financial results on November 4, 2025. The company provides essential next-generation technologies, including SomaScan, mass cytometry, and microfluidics, to accelerate medical research and improve patient outcomes.
2025-10-21 11:00
